RxDoctor Payments Data

Jorge Garcia-Gregory, MD

Cardiovascular Disease · Houston, TXNPI 1760486450

Payments from drug & device makers

$12,809in general payments, 2019–2025

Across 656 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Amgen$1K
  • Pfizer$1K
  • Biosense Webster, Inc.$877
  • E.r. Squibb & Sons, L.L.C.$836
  • Novartis$770
  • plus $6K from 36 others

What the payments were for

  • Food & beverage$12,784100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,809 in reported general payments places this provider in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

See all cardiovascular disease providers in Texas

Medicare billing

Part B allowed, 2024
$159,618
Medicare patients
139
Services billed
782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban211$254,297
EntrestoSacubitril/Valsartan61$82,741
VascepaIcosapent Ethyl84$60,584
Repatha PushtronexEvolocumab55$52,389
Repatha SureclickEvolocumab53$47,844
XareltoRivaroxaban27$32,568
JardianceEmpagliflozin19$22,498
FarxigaDapagliflozin Propanediol12$17,554
EdarbyclorAzilsartan Med/Chlorthalidone26$16,207
LivaloPitavastatin Calcium22$15,118
Icosapent Ethyl22$11,528
EdarbiAzilsartan Medoxomil22$10,699
Ezetimibe209$5,705
Pitavastatin Calcium14$5,161
Metoprolol Succinate291$4,920

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,084$254,297211 claims
NovartisEntresto$770$82,74161 claims
Johnson & JohnsonXarelto$1,749$32,56827 claims
Arbor Pharmaceuticals, Inc.Edarbyclor, Edarbi$104$26,90648 claims
Boehringer IngelheimJardiance$611$22,49819 claims
AstraZenecaFarxiga$156$17,55412 claims
Kowa Pharmaceuticals America, Inc.Livalo$349$15,11822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,515 cardiovascular disease providers in Texas.

Other cardiovascular disease in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →